Mesoporous Silica Nanoparticles Are Nanocarrier for Drug Loading and Induces Cell Death in Breast Cancer

2021 ◽  
pp. 225-245
Author(s):  
Lakshminarasimhan Harini ◽  
Karthikeyan Bose ◽  
T. Mohan Viswanathan ◽  
Nachimuthu Senthil Kumar ◽  
Krishnan Sundar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Loading

scholarly journals Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells

Nanomaterials ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1298
Author(s):  
Vicente Candela-Noguera ◽  
Gema Vivo-Llorca ◽  
Borja Díaz de Greñu ◽  
María Alfonso ◽  
Elena Aznar ◽  
...  
Keyword(s):  
Cell Death ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Tumor Cells ◽  
Mesoporous Silica Nanoparticles ◽  
Combined Treatment ◽  
Bond Rupture ◽  
Enzyme Prodrug Therapy ◽  
Bacterial Gene ◽  
Reducing Environment

We report herein a gene-directed enzyme prodrug therapy (GDEPT) system using gated mesoporous silica nanoparticles (MSNs) in an attempt to combine the reduction of side effects characteristic of GDEPT with improved pharmacokinetics promoted by gated MSNs. The system consists of the transfection of cancer cells with a plasmid controlled by the cytomegalovirus promoter, which promotes β-galactosidase (β-gal) expression from the bacterial gene lacZ (CMV-lacZ). Moreover, dendrimer-like mesoporous silica nanoparticles (DMSNs) are loaded with the prodrug doxorubicin modified with a galactose unit through a self-immolative group (DOXO-Gal) and modified with a disulfide-containing polyethyleneglycol gatekeeper. Once in tumor cells, the reducing environment induces disulfide bond rupture in the gatekeeper with the subsequent DOXO-Gal delivery, which is enzymatically converted by β-gal into the cytotoxic doxorubicin drug, causing cell death. The combined treatment of the pair enzyme/DMSNs-prodrug are more effective in killing cells than the free prodrug DOXO-Gal alone in cells transfected with β-gal.

scholarly journals Polymeric Mesoporous Silica Nanoparticles for Enhanced Delivery of 5-Fluorouracil In Vitro

Pharmaceutics ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 288 ◽  
Author(s):  
Thashini Moodley ◽  
Moganavelli Singh
Keyword(s):  
Side Effects ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Therapeutic Potential ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Loading ◽  
Hek293 Cells ◽  
Cancer Drug ◽  
Delivery Vehicles

There is a need for the improvement of conventional cancer treatment strategies by incorporation of targeted and non-invasive procedures aimed to reduce side-effects, drug resistance, and recurrent metastases. The anti-cancer drug, 5-fluorouracil (5-FU), is linked to a variety of induced-systemic toxicities due to its lack of specificity and potent administration regimens, necessitating the development of delivery vehicles that can enhance its therapeutic potential, while minimizing associated side-effects. Polymeric mesoporous silica nanoparticles (MSNs) have gained popularity as delivery vehicles due to their high loading capacities, biocompatibility, and good pharmacokinetics. MSNs produced in this study were functionalized with the biocompatible polymers, chitosan, and poly(ethylene)glycol to produce monodisperse NPs of 36–65 nm, with a large surface area of 710.36 m2/g, large pore volume, diameter spanning 9.8 nm, and a favorable zeta potential allowing for stability and enhanced uptake of 5-FU. Significant drug loading (0.15–0.18 mg5FU/mgmsn), controlled release profiles (15–65%) over 72 hours, and cell specific cytotoxicity in cancer cells (Caco-2, MCF-7, and HeLa) with reduced cell viability (≥50%) over the non-cancer (HEK293) cells were established. Overall, these 5FU-MSN formulations have been shown to be safe and effective delivery systems in vitro, with potential for in vivo applications.

scholarly journals Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+Breast Cancer

2015 ◽  
Vol 25 (18) ◽  
pp. 2646-2659 ◽  
Author(s):  
Worapol Ngamcherdtrakul ◽  
Jingga Morry ◽  
Shenda Gu ◽  
David J. Castro ◽  
Shaun M. Goodyear ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Sirna Delivery ◽  
Cationic Polymer ◽  
Her2 Breast Cancer

scholarly journals Effectiveness of Diverse Mesoporous Silica Nanoparticles as Potent Vehicles for the Drug L-DOPA

Materials ◽  
2019 ◽  
Vol 12 (19) ◽  
pp. 3202
Author(s):  
Sumita Swar ◽  
Veronika Máková ◽  
Ivan Stibor
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Loading ◽  
Vis Spectroscopy ◽  
Bet Analysis ◽  
Silica Materials ◽  
Different Types ◽  
Mesoporous Silica Materials ◽  
Drug Vehicle

Our study was focused on the synthesis of selective mesoporous silica nanoparticles (MSNs: MCM-41, MCM-48, SBA-15, PHTS, MCF) that are widely studied for drug delivery. The resulting mesoporous surfaces were conveniently prepared making use of verified synthetic procedures. The MSNs thus obtained were characterized by Brunauer-Emmett-Teller (BET) analysis and scanning electron microscopy (SEM). The selected MSNs with various pore diameters and morphologies were examined to evaluate the capability of L-DOPA drug loading and release. L-DOPA is a well-known drug for Parkinson’s disease. The L-DOPA drug loading and release profiles were measured by UV-VIS spectroscopy and SBA-15 was proved to be the most effective amongst all the different types of tested mesoporous silica materials as L-DOPA drug vehicle.

scholarly journals Large Pore Mesoporous Silica and Organosilica Nanoparticles for Pepstatin A Delivery in Breast Cancer Cells

Molecules ◽  
2019 ◽  
Vol 24 (2) ◽  
pp. 332 ◽  
Author(s):  
Saher Rahmani ◽  
Jelena Budimir ◽  
Mylene Sejalon ◽  
Morgane Daurat ◽  
Dina Aggad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Cathepsin D ◽  
Breast Cancer Cells ◽  
Potent Inhibitor ◽  
Mesoporous Silica Nanoparticles ◽  
Sol Gel ◽  
Pepstatin A

(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides.

Sign in / Sign up

Export Citation Format

Share Document